AIM ImmunoTech Secures $8.5M and Regains NYSE American Listing Compliance
AIM•AIM ImmunoTech secured approximately $8.5 million in equity through warrant exercises and private placements in May and June, boosting stockholders’ equity above the $6 million NYSE American minimum. The NYSE American removed the “.BC” indicator and restored full compliance with continued listing standards.
1. Equity Raises and Compliance Restoration
On May 7, AIM entered into a warrant exercise inducement agreement raising about $3.5 million in gross proceeds at a reduced exercise price. Subsequent private placements on May 21 and June 10 generated approximately $2.4 million and $2.6 million respectively, lifting stockholders’ equity above the $6.0 million NYSE American threshold.
2. Warrant Exercise Inducement and Private Placements
The warrant inducement allowed holders to exercise existing warrants for cash at a lower strike, while the May 21 placement issued 7,519,351 common shares with Class I warrants for $2.4 million. On June 10, AIM sold 2,554,119 shares plus pre-funded and Class J warrants to raise an additional $2.6 million.
3. Impact on Trading Status and Governance
On June 12, NYSE American confirmed AIM resolved deficiencies under Sections 1003(a)(i)-(iii), removing the “.BC” tag and delisting the issuer from its noncompliance list. AIM will continue under standard monitoring and maintain financial discipline and governance going forward.
